GlobalData says UK fears over antibiotic resistance is "valid conclusion"

4 July 2014
globaldata-logo-big

Earlier this week,  UK Prime Minister David Cameron revealed the formation of an independent review panel to address the growing threat of antibiotic resistance.

Responding to the announcement, Christopher Pace, GlobalData’s analyst covering infectious diseases, said: "Mr Cameron’s claim that inaction will result in “an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine” is a valid conclusion that has been echoed by experts interviewed by GlobalData.

Over the last two decades, many large pharmaceutical companies have abandoned antibiotic research due to the risky and prolonged R&D process, combined with the difficulty in commanding premium-pricing and the short durations of therapy, he pointed out.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical